Journal: Haematologica
This publication reviews the current landscape of JAK inhibitors in the treatment of myelofibrosis, a myeloproliferative neoplasm characterized by JAK/STAT pathway dysregulation. This condition causes symptoms such as splenomegaly, anemia, and constitutional issues.
While hematopoietic stem cell transplant remains the only curative option, JAK inhibitors—including ruxolitinib, fedratinib, pacritinib, and momelotinib—have significantly improved symptom management and spleen size reduction. Some of these drugs also offer additional benefits for anemia.
The review highlights:
- Distinct efficacy and safety profiles of the different JAK inhibitors
- Limited head-to-head trial data comparing these agents
- Emerging real-world experience that complicates first-line choice and treatment sequencing
Using four hypothetical patient cases, the authors emphasize the importance of tailoring JAK inhibitor selection based on individual clinical characteristics to optimize long-term outcomes as treatment options continue to evolve.